Work

Abstract 318: The combination of STX-478 and lorlatinib for the treatment of PIK3CA mutant colorectal cancer.

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-318

Authors: Addison T. Zick, Alexa E. Schmitz, Cheri A. Pasch, Dustin A. Deming

Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7148820790

Cites:

Cited by:

Related to: